India’s drug regulator CDSCO flagged 186 medicines, including paracetamol and diabetes drugs, as substandard in May 2025, raising serious concerns about drug safety and manufacturing practices.

The Drugs Controller General of India has urged the cosmetics industry to follow regulations strictly and avoid making misleading claims.

India bans manufacture and sale of 35 painkillers, nutrition supplements, anti-diabetics drugs The ban was issued after the regulator found that some FDC drugs were licensed for manufacture, sale ...

The Drugs & Cosmetics Act, 1940 gives the state drug inspectors the power to call for sales records (S. 18A & S.18B) of the NSQ batch and seize the NSQ drugs [S. 22 (c)] so that they cannot be ...

Months after policy freeze, the DTAB is reconstituted to take up pending issues like AMR, GMP, spurious drugs and more—marking a critical moment for India’s $50 billion pharma industry.

They have also been asked to review their approval process for such fixed dose combination drugs (FDC) and ensure strict compliance of the provisions of the Drugs and Cosmetics Act 1940 and rules.

Apex drugs regulatory body CDSCO has directed drug controllers of all states and Union territories to stop manufacture, sale and distribution of unapproved 35 fixed-dose combination drugs that include ...

Delhi-based South Chemists & Distributors Association (SCDA), the pharmaceutical traders' organisation, has once again requested the Union ministry of health and family welfare to take immediate ...

Karnataka Minister for Health and Family Welfare Dinesh Gundu Rao stated that 87 pharmacies have been suspended, and three have been permanently shut down.

Over 100 MSME drug firms modernizing their pharma unit as per WHO standards The government revised Schedule M under the Drugs & Cosmetic Act in 2023 to make it mandatory for companies to follow ...

Govt bans manufacture, sale of 35 fixed-dose combination drugs CDSCO directs States to halt sale of unapproved FDC drugs, emphasizing safety and compliance with drug regulations.

This has resulted in a lack of uniform enforcement of the provision of NDCT Rules 2019 under the Drugs and Cosmetics Act 1940 across the country, the letter pointed out.